RxDoctor Payments Data

Ming Cheung, MD

Internal Medicine · Flushing, NYNPI 1518911239

Payments from drug & device makers

$1,074in general payments, 2019–2025

Across 53 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$228
  • Amgen$194
  • Amarin Pharma, Inc.$160
  • GSK$125
  • Gilead$114
  • AbbVie$77
  • plus $177 from 5 others

What the payments were for

  • Food & beverage$1,074100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck12$228
Amgen(2 entities)10$194
Amarin Pharma, Inc.8$160
GSK5$125
Gilead5$114
AbbVie3$77
Exact Sciences3$60
Sanofi Pasteur Inc.3$50
Novo Nordisk2$37
Phadia US Inc.1$16
Seqirus USA Inc1$14

How this compares

$1,074 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$259,440
Medicare patients
352
Services billed
2,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Epolamine51$37,577
VascepaIcosapent Ethyl80$30,447
JanuviaSitagliptin Phosphate12$10,024
Atorvastatin Calcium160$1,152
Ammonium Lactate37$1,001
Amlodipine Besylate131$583
Fluticasone Propionate55$578
Losartan Potassium68$470
Omeprazole50$449
Metoprolol Succinate36$403
Azelastine Hcl22$353
Diclofenac Sodium17$327
Rosuvastatin Calcium33$317
Tamsulosin Hcl28$315
Atenolol28$267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$228$10,02412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →